Himalaya: Listen. Learn. Grow.

4.8K Ratings
Open In App
title

Pharmacy to Dose: The Critical Care Podcast

Nick Peters

0
Followers
0
Plays
Pharmacy to Dose: The Critical Care Podcast

Pharmacy to Dose: The Critical Care Podcast

Nick Peters

0
Followers
0
Plays
OVERVIEWEPISODESYOU MAY ALSO LIKE

Details

About Us

Pharmacy to Dose: The Critical Care Podcast provides information related to critical care and its pharmacotherapy in a fun and entertaining manner while creating a network of Pharmacists and critical care practitioners. New episodes are released every two weeks. Each episode we bring in a special guest to discuss a disease state or medication, with your host Nick Peters.

Latest Episodes

Pediatric Critical Care Part I

Pediatric Critical Care Part ISpecial Guest: Joseph LaRochelle, PharmD, BCPPS, FCCPResource List: https://pharmacytodose.files.wordpress.com/2020/08/pediatric-critical-care-part-i-resources.pdf04:22 – Applying adult principles to kids?; 06:01 – Neonatal/pediatric vital signs; 10:25 – Pediatric/neonatal PK changes; 20:34 – Cytochrome P450 metabolism; 31:20 – Pediatric renal function/elimination; 44:22 – Pediatric v. adult dosing; 51:10 – Pediatric medication safety principles; 60:45 – Memorizing pediatric dosing; 70:13 – Pediatric weights; 74:26 – Pediatric Pharmacist training; 84:20 – Advice for Pharmacists; 86:43 – Take-home pointsPharmacyToDose.Com@PharmacyToDose on Twitter/InstagramPharmacyToDose@Gmail.com

98 MIN1 d ago
Comments
Pediatric Critical Care Part I

Ventricular Arrhythmias

Ventricular ArrhythmiasSpecial Guest: Matthew Wanat, PharmD, BCPS, BCCCP, FCCMShow Notes: https://pharmacytodose.files.wordpress.com/2020/07/ventricular-arrhythmias-show-notes.pdfReference List: https://pharmacytodose.files.wordpress.com/2020/07/ventricular-arrhythmias-references.pdf04:00 – What are arrhythmias?; 05:30 – Why are arrhythmias harmful/dangerous?; 06:58 – Risk factors; 09:12 – Common atrial arrhythmias; 10:19 – General arrhythmia treatment principles; 12:45 – When to use rhythm control for AF; 14:37 – Adenosine; 22:04 – Non-sustained VT/PVCs; 27:00 – Monomorphic v. Polymorphic VT; 30:53 – Torsades de Pointes; 34:16 – QTc prolongation; 42:18 – VF v. VT; 43:29 – Pulseless VT/VF; 49:30 – Amiodarone; 54:55 – Lidocaine/Mextiletine; 64:10 – Sotalol; 67:40 – Sodium channel blockers; 70:25 – Isoproterenol; 73:43 – BB/CCB; 78:29 – Long-term management; 80:34 – Stroke risk with ventricular arrhythmias; 82:20 – Prevention; 83:40 – EKG Interpretation; 86:48 – Step-wise approach; 88:13 – Take-home points; 90:00 – Small talkPharmacyToDose.Com@PharmacyToDose on Twitter/InstagramPharmacyToDose@Gmail.com

99 MIN2 w ago
Comments
Ventricular Arrhythmias

White Coats for Black Lives

White Coats for Black LivesSpecial Guests:Earnest Alexander, PharmD, BCCCP, FCCMSheriff Gbadamosi, PharmDJason Jones, PharmD, BCPS, BCCCPReference List: https://pharmacytodose.files.wordpress.com/2020/07/white-coats-for-black-lives-references.pdf05:01 – How did we get here?; 27:16 – What emotions have you felt over recent events?; 45:40 – Why is this movement different?; 51:30 – Are these protests necessary/effective to enact change?; 59:20 – Inequality within the criminal justice system; 71:50 – Differences in treatment/outcomes for black patients; 83:43 – Systemic racism within US healthcare system; 87:09 – Is this a public health issue?; 91:55 – Importance of the diversity on the healthcare team; 95:35 – Increased pressure/stress being a black team member; 100:20 – Being an anti-racist; 104:40 – “All Lives Matter”; 109:55 – Powerful/Impactful media recommendations or further reading; 118:37 – Being a productive ally to the Black Lives Matter movement; 123:38 – Final thoughtsPharmacyToDose.Com@PharmacyToDose on Twitter/InstagramPharmacyToDose@Gmail.com

132 MINJUL 4
Comments
White Coats for Black Lives

Medication Dosing in CRRT

CRRT Medication DosingSpecial Guest: Bruce Mueller, PharmD, FCCP, FASN, FNKFShow Notes: https://pharmacytodose.files.wordpress.com/2020/06/medication-dosing-in-crrt-show-notes.pdfReference List: https://pharmacytodose.files.wordpress.com/2020/06/medication-dosing-in-crrt-references.pdf04:05 – Effect of AKI on patient outcomes; 08:40 – Different RRT modalities; 13:56 – How long has CRRT been used?; 17:35 – CRRT for all ICU patients?; 22:06 – When to avoid CRRT; 23:28 – CRRT definitions; 43:20 – Medication underdosing on CRRT; 51:27 – Older CRRT dosing studies v. newer studies; 54:29 – Drug properties that increase CRRT clearance; 58:36 – Does CRRT modality affect medication clearance?; 60:02 – Antibiotic retiming; 61:20 – Drug reference dosing recommendations; 64:20 – Dosing when patient is on CRRT and not in AKI; 66:40 – Anticoagulation for CRRT; 75:13 – Hybrid CRRT modalities; 81:45 – General dosing considerations; 83:23 – CRRT dosing drug referencesPharmacyToDose.Com@PharmacyToDose on Twitter/InstagramPharmacyToDose@Gmail.com

92 MINJUN 18
Comments
Medication Dosing in CRRT

Aneurysmal Subarachnoid Hemorrhage

Aneurysmal Subarachnoid HemorrhageSpecial Guest: Casey May, PharmD, BCCCPShow Notes: https://pharmacytodose.files.wordpress.com/2020/06/asah-show-notes.pdfReference List: https://pharmacytodose.files.wordpress.com/2020/06/asah-references.pdf02:51 – Types of intracerebral bleeds; 06:19 – Types of subarachnoid hemorrhage; 08:25 – Pathophysiology of aSAH; 10:45 – Risk factors; 12:48 – Classic aSAH presentation; 16:36 – Classificiation systems; 22:25 – Prioritizating acute management of aSAH; 25:15 – Blood pressure goals; 26:21 – Preferred anti-HTN agent?; 28:25 – Biggest concerns with anti-HTN agents; 31:08 – ICP management; 35:40 – Surgical clipping v. Endovascular coiling; 42:51 – Cerebral vasospasms and delayed cerebral ischemia; 55:07 – Nimodipine in aSAH; 68:20 – DVT prophylaxis; 73:48 – Seizure prophylaxis; 76:30 – Augmented renal clearance; 83:56 – Take-home pointsPharmacyToDose.Com@PharmacyToDose on Twitter/InstagramPharmacyToDose@Gmail.com

94 MINJUN 4
Comments
Aneurysmal Subarachnoid Hemorrhage

Acute Liver Failure

Acute Liver FailureSpecial Guest: Stephanie Bass, PharmD, BCPS, BCCCPShow Notes: https://pharmacytodose.files.wordpress.com/2020/05/acute-liver-failure-show-notes.pdfReference List: https://pharmacytodose.files.wordpress.com/2020/05/acute-liver-failure-references.pdf03:05 – Stephanie’s interest in the liver; 05:54 – Diagnosing ALF; 07:20 – Does having liver disease increase ALF risk?; 09:00 – Ultimate goal when treating ALF; 10:07 – Patient presentation; 11:58 – Common causes of ALF; 13:30 – ICP and cerebral edema management in ALF; 15:50 – PAD management in ALF; 18:55 – Acute hepatic encephalopathy management; 21:00 – Trending ammonia levels?; 22:25 – NAC for APAP overdose ALF; 27:11 – NAC for non-APAP overdose ALF; 30:23 – Albumin for ALF fluid resuscitation; 34:33 – Vasopressor use; 36:53 – Blood pressure goals; 40:00 – TEG for bleeding risk assessment; 43:45 – Hemostatic agents for coagulopathy; 46:18 – Anticoagulant of choice; 47:59 – Hepatic dose adjustments; 52:12 – Medication dosing with MARS/RRT; 54:00 – Medications to avoid; 56:02 – Transplant considerations; 58:24 – Take-home pointsPharmacyToDose.Com@PharmacyToDose on Twitter/InstagramPharmacyToDose@Gmail.com

67 MINMAY 20
Comments
Acute Liver Failure

Critical Care Management of COVID-19

Critical Care Management of COVID-19Special Guests: Drayton Hammond, PharmD, MBA, MSc, BCPS, BCCCP, FCCMPeter Nikolos, PharmDShow Notes: https://pharmacytodose.files.wordpress.com/2020/04/covid-19-complications-show-notes.pdfMechanical Ventilation (Drayton)08:00 – Non-COVID-19 PAD management; 11:16 – COVID-19 PAD management; 18:22 – Managing PAD drug shortages; 22:38 – Opioid conservation strategies; 26:08 – Propofol conservation strategies; 29:08 – Hypertriglyceridemia with propofol; 32:10 – Risk of PRIS; 34:30 – Ketamine; 41:05 – NMBA use and shortage; 46:00 – PPE conservation; 49:00 – Bronchodilator use for COVID-19; 50:28 – Inhaled anticoagulants; 52:46 – Inhaled pulmonary vasodilators; 54:17 – Advice for COVID-19 managementCardiovascular (Peter)67:20 – Current shortages; 71:05 – First-line vasopressor; 73:25 – Vasopressor compounding and utilization changes; 74:50 – Smart pump management; 77:15 – Vasopressor shortage management; 79:45 – Anticoagulation treatment strategy; 85:30 – Anticoagulation monitoring; 86:28 – Anticoagulation in ECMO/CRRT; 88:20 – PE causing rapid decompensation?; 90:25 – Alternate anticoagulants; 92:52 – Thrombolytics in ACS; 98:13 – Code response changes; 100:05 – ACE-I/ARB use in COVID-19; 103:41 – NSAID use in COVID-19; 105:15 – Statin use in COVID-19; 107:25 – Challenges from virtual rounding; 110:20 – Key points on COVID-19 managementPharmacyToDose.Com@PharmacyToDose on Twitter/InstagramPharmacyToDose@Gmail.com

120 MINAPR 27
Comments
Critical Care Management of COVID-19

Research Principles for COVID-19

Research Principles for COVID-19Special Guest: Todd Miano, PharmD, PhDShow Notes: https://pharmacytodose.files.wordpress.com/2020/04/research-principles-show-notes.pdf05:19 – Todd’s interest in research/statistics; 09:18 – How Todd analyzes a research article; 24:22 – Why so much low-quality research for COVID-19?; 28:18 – In vitro v. in vivo; 32:34 – Risk of study errors in low-quality research; 45:43 – Publication bias; 51:50 – Interpreting outcome-based studies when patients are still critically ill; 54:46 – Ideal primary outcome for COVID-19 trials; 57:50 – Applying information from international data to US patients; 61:02 – What is the risk of using experimental drug treatments?; 68:54 – Effect of COVID-19 on non-COVID research; 70:33 – Advice for starting COVID-19 research; 73:43 – Research red flags; 75:46 – Keeping up with COVID-19 literature; 79:09 – Quarantine entertainment recommendationsPharmacyToDose.Com@PharmacyToDose on Twitter/InstagramPharmacyToDose@Gmail.com

84 MINAPR 23
Comments
Research Principles for COVID-19

Cerebral Edema Treatment

Cerebral Edema TreatmentSpecial Guest: Aaron Cook, PharmD, BCCCP, BCPS, FCCP, FKSHP, FNCSShow Notes: https://pharmacytodose.files.wordpress.com/2020/04/treatment-of-cerebral-edema-show-notes.pdfGuideline Development06:18 – How did the content and the chairs for this guideline get chosen?; 08:40 – How long were you working on these guidelines?; 09:40 – How are panel members chosen for the guidelines?; 11:20 – Is the research librarian underrated?; 13:31 – GRADE methodology and PICO formatting; 17:24 – Has this changed your research habits or ideas?; 21:40 – Challenges from meeting virtually when developing the guidelines; 23:53 – How were disagreements settled within the working group?Management of Cerebral Edema 27:45 – Cerebral edema and elevated ICP; 29:22 – Refractory cerebral edema management; 31:59 – How long was the initial question list?; 35:03 – Quality of evidence; 37:58 – Patient subgroup with the most evidence; 40:10 – Should we be driving up patients’ sodium levels?; 44:56 – Is there a preferred hyperosmolar agent?; 47:45 – Mannitol in acute ischemic stroke; 49:00 – Osmolar therapy and neurologic outcomes; 51:16 – HTS administration; 54:30 – HTS ADE and monitoring; 57:10 – Mannitol osmolality monitoring; 58:20 – Hyperosmolar therapy ADE prevention; 61:00 – Guideline key take-aways; 62:20 – Common research issuesPharmacyToDose.Com@PharmacyToDose on Twitter/InstagramPharmacyToDose@Gmail.com

71 MINAPR 16
Comments
Cerebral Edema Treatment

COVID-19

COVID-19 Special Guest: Andrew Barnes, PharmDDr. Andrew Barnes joins the podcast to discuss the effects of COVID-19. We talk about what Seattle and the University of Washington are doing to help treat this national pandemic. Plus there are plenty of tips throughout the episode for ways you can adapt to COVID-19 in your hospital or health system.PharmacyToDose.Com@PharmacyToDose on Twitter/InstagramPharmacyToDose@Gmail.com

55 MINMAR 26
Comments
COVID-19

Latest Episodes

Pediatric Critical Care Part I

Pediatric Critical Care Part ISpecial Guest: Joseph LaRochelle, PharmD, BCPPS, FCCPResource List: https://pharmacytodose.files.wordpress.com/2020/08/pediatric-critical-care-part-i-resources.pdf04:22 – Applying adult principles to kids?; 06:01 – Neonatal/pediatric vital signs; 10:25 – Pediatric/neonatal PK changes; 20:34 – Cytochrome P450 metabolism; 31:20 – Pediatric renal function/elimination; 44:22 – Pediatric v. adult dosing; 51:10 – Pediatric medication safety principles; 60:45 – Memorizing pediatric dosing; 70:13 – Pediatric weights; 74:26 – Pediatric Pharmacist training; 84:20 – Advice for Pharmacists; 86:43 – Take-home pointsPharmacyToDose.Com@PharmacyToDose on Twitter/InstagramPharmacyToDose@Gmail.com

98 MIN1 d ago
Comments
Pediatric Critical Care Part I

Ventricular Arrhythmias

Ventricular ArrhythmiasSpecial Guest: Matthew Wanat, PharmD, BCPS, BCCCP, FCCMShow Notes: https://pharmacytodose.files.wordpress.com/2020/07/ventricular-arrhythmias-show-notes.pdfReference List: https://pharmacytodose.files.wordpress.com/2020/07/ventricular-arrhythmias-references.pdf04:00 – What are arrhythmias?; 05:30 – Why are arrhythmias harmful/dangerous?; 06:58 – Risk factors; 09:12 – Common atrial arrhythmias; 10:19 – General arrhythmia treatment principles; 12:45 – When to use rhythm control for AF; 14:37 – Adenosine; 22:04 – Non-sustained VT/PVCs; 27:00 – Monomorphic v. Polymorphic VT; 30:53 – Torsades de Pointes; 34:16 – QTc prolongation; 42:18 – VF v. VT; 43:29 – Pulseless VT/VF; 49:30 – Amiodarone; 54:55 – Lidocaine/Mextiletine; 64:10 – Sotalol; 67:40 – Sodium channel blockers; 70:25 – Isoproterenol; 73:43 – BB/CCB; 78:29 – Long-term management; 80:34 – Stroke risk with ventricular arrhythmias; 82:20 – Prevention; 83:40 – EKG Interpretation; 86:48 – Step-wise approach; 88:13 – Take-home points; 90:00 – Small talkPharmacyToDose.Com@PharmacyToDose on Twitter/InstagramPharmacyToDose@Gmail.com

99 MIN2 w ago
Comments
Ventricular Arrhythmias

White Coats for Black Lives

White Coats for Black LivesSpecial Guests:Earnest Alexander, PharmD, BCCCP, FCCMSheriff Gbadamosi, PharmDJason Jones, PharmD, BCPS, BCCCPReference List: https://pharmacytodose.files.wordpress.com/2020/07/white-coats-for-black-lives-references.pdf05:01 – How did we get here?; 27:16 – What emotions have you felt over recent events?; 45:40 – Why is this movement different?; 51:30 – Are these protests necessary/effective to enact change?; 59:20 – Inequality within the criminal justice system; 71:50 – Differences in treatment/outcomes for black patients; 83:43 – Systemic racism within US healthcare system; 87:09 – Is this a public health issue?; 91:55 – Importance of the diversity on the healthcare team; 95:35 – Increased pressure/stress being a black team member; 100:20 – Being an anti-racist; 104:40 – “All Lives Matter”; 109:55 – Powerful/Impactful media recommendations or further reading; 118:37 – Being a productive ally to the Black Lives Matter movement; 123:38 – Final thoughtsPharmacyToDose.Com@PharmacyToDose on Twitter/InstagramPharmacyToDose@Gmail.com

132 MINJUL 4
Comments
White Coats for Black Lives

Medication Dosing in CRRT

CRRT Medication DosingSpecial Guest: Bruce Mueller, PharmD, FCCP, FASN, FNKFShow Notes: https://pharmacytodose.files.wordpress.com/2020/06/medication-dosing-in-crrt-show-notes.pdfReference List: https://pharmacytodose.files.wordpress.com/2020/06/medication-dosing-in-crrt-references.pdf04:05 – Effect of AKI on patient outcomes; 08:40 – Different RRT modalities; 13:56 – How long has CRRT been used?; 17:35 – CRRT for all ICU patients?; 22:06 – When to avoid CRRT; 23:28 – CRRT definitions; 43:20 – Medication underdosing on CRRT; 51:27 – Older CRRT dosing studies v. newer studies; 54:29 – Drug properties that increase CRRT clearance; 58:36 – Does CRRT modality affect medication clearance?; 60:02 – Antibiotic retiming; 61:20 – Drug reference dosing recommendations; 64:20 – Dosing when patient is on CRRT and not in AKI; 66:40 – Anticoagulation for CRRT; 75:13 – Hybrid CRRT modalities; 81:45 – General dosing considerations; 83:23 – CRRT dosing drug referencesPharmacyToDose.Com@PharmacyToDose on Twitter/InstagramPharmacyToDose@Gmail.com

92 MINJUN 18
Comments
Medication Dosing in CRRT

Aneurysmal Subarachnoid Hemorrhage

Aneurysmal Subarachnoid HemorrhageSpecial Guest: Casey May, PharmD, BCCCPShow Notes: https://pharmacytodose.files.wordpress.com/2020/06/asah-show-notes.pdfReference List: https://pharmacytodose.files.wordpress.com/2020/06/asah-references.pdf02:51 – Types of intracerebral bleeds; 06:19 – Types of subarachnoid hemorrhage; 08:25 – Pathophysiology of aSAH; 10:45 – Risk factors; 12:48 – Classic aSAH presentation; 16:36 – Classificiation systems; 22:25 – Prioritizating acute management of aSAH; 25:15 – Blood pressure goals; 26:21 – Preferred anti-HTN agent?; 28:25 – Biggest concerns with anti-HTN agents; 31:08 – ICP management; 35:40 – Surgical clipping v. Endovascular coiling; 42:51 – Cerebral vasospasms and delayed cerebral ischemia; 55:07 – Nimodipine in aSAH; 68:20 – DVT prophylaxis; 73:48 – Seizure prophylaxis; 76:30 – Augmented renal clearance; 83:56 – Take-home pointsPharmacyToDose.Com@PharmacyToDose on Twitter/InstagramPharmacyToDose@Gmail.com

94 MINJUN 4
Comments
Aneurysmal Subarachnoid Hemorrhage

Acute Liver Failure

Acute Liver FailureSpecial Guest: Stephanie Bass, PharmD, BCPS, BCCCPShow Notes: https://pharmacytodose.files.wordpress.com/2020/05/acute-liver-failure-show-notes.pdfReference List: https://pharmacytodose.files.wordpress.com/2020/05/acute-liver-failure-references.pdf03:05 – Stephanie’s interest in the liver; 05:54 – Diagnosing ALF; 07:20 – Does having liver disease increase ALF risk?; 09:00 – Ultimate goal when treating ALF; 10:07 – Patient presentation; 11:58 – Common causes of ALF; 13:30 – ICP and cerebral edema management in ALF; 15:50 – PAD management in ALF; 18:55 – Acute hepatic encephalopathy management; 21:00 – Trending ammonia levels?; 22:25 – NAC for APAP overdose ALF; 27:11 – NAC for non-APAP overdose ALF; 30:23 – Albumin for ALF fluid resuscitation; 34:33 – Vasopressor use; 36:53 – Blood pressure goals; 40:00 – TEG for bleeding risk assessment; 43:45 – Hemostatic agents for coagulopathy; 46:18 – Anticoagulant of choice; 47:59 – Hepatic dose adjustments; 52:12 – Medication dosing with MARS/RRT; 54:00 – Medications to avoid; 56:02 – Transplant considerations; 58:24 – Take-home pointsPharmacyToDose.Com@PharmacyToDose on Twitter/InstagramPharmacyToDose@Gmail.com

67 MINMAY 20
Comments
Acute Liver Failure

Critical Care Management of COVID-19

Critical Care Management of COVID-19Special Guests: Drayton Hammond, PharmD, MBA, MSc, BCPS, BCCCP, FCCMPeter Nikolos, PharmDShow Notes: https://pharmacytodose.files.wordpress.com/2020/04/covid-19-complications-show-notes.pdfMechanical Ventilation (Drayton)08:00 – Non-COVID-19 PAD management; 11:16 – COVID-19 PAD management; 18:22 – Managing PAD drug shortages; 22:38 – Opioid conservation strategies; 26:08 – Propofol conservation strategies; 29:08 – Hypertriglyceridemia with propofol; 32:10 – Risk of PRIS; 34:30 – Ketamine; 41:05 – NMBA use and shortage; 46:00 – PPE conservation; 49:00 – Bronchodilator use for COVID-19; 50:28 – Inhaled anticoagulants; 52:46 – Inhaled pulmonary vasodilators; 54:17 – Advice for COVID-19 managementCardiovascular (Peter)67:20 – Current shortages; 71:05 – First-line vasopressor; 73:25 – Vasopressor compounding and utilization changes; 74:50 – Smart pump management; 77:15 – Vasopressor shortage management; 79:45 – Anticoagulation treatment strategy; 85:30 – Anticoagulation monitoring; 86:28 – Anticoagulation in ECMO/CRRT; 88:20 – PE causing rapid decompensation?; 90:25 – Alternate anticoagulants; 92:52 – Thrombolytics in ACS; 98:13 – Code response changes; 100:05 – ACE-I/ARB use in COVID-19; 103:41 – NSAID use in COVID-19; 105:15 – Statin use in COVID-19; 107:25 – Challenges from virtual rounding; 110:20 – Key points on COVID-19 managementPharmacyToDose.Com@PharmacyToDose on Twitter/InstagramPharmacyToDose@Gmail.com

120 MINAPR 27
Comments
Critical Care Management of COVID-19

Research Principles for COVID-19

Research Principles for COVID-19Special Guest: Todd Miano, PharmD, PhDShow Notes: https://pharmacytodose.files.wordpress.com/2020/04/research-principles-show-notes.pdf05:19 – Todd’s interest in research/statistics; 09:18 – How Todd analyzes a research article; 24:22 – Why so much low-quality research for COVID-19?; 28:18 – In vitro v. in vivo; 32:34 – Risk of study errors in low-quality research; 45:43 – Publication bias; 51:50 – Interpreting outcome-based studies when patients are still critically ill; 54:46 – Ideal primary outcome for COVID-19 trials; 57:50 – Applying information from international data to US patients; 61:02 – What is the risk of using experimental drug treatments?; 68:54 – Effect of COVID-19 on non-COVID research; 70:33 – Advice for starting COVID-19 research; 73:43 – Research red flags; 75:46 – Keeping up with COVID-19 literature; 79:09 – Quarantine entertainment recommendationsPharmacyToDose.Com@PharmacyToDose on Twitter/InstagramPharmacyToDose@Gmail.com

84 MINAPR 23
Comments
Research Principles for COVID-19

Cerebral Edema Treatment

Cerebral Edema TreatmentSpecial Guest: Aaron Cook, PharmD, BCCCP, BCPS, FCCP, FKSHP, FNCSShow Notes: https://pharmacytodose.files.wordpress.com/2020/04/treatment-of-cerebral-edema-show-notes.pdfGuideline Development06:18 – How did the content and the chairs for this guideline get chosen?; 08:40 – How long were you working on these guidelines?; 09:40 – How are panel members chosen for the guidelines?; 11:20 – Is the research librarian underrated?; 13:31 – GRADE methodology and PICO formatting; 17:24 – Has this changed your research habits or ideas?; 21:40 – Challenges from meeting virtually when developing the guidelines; 23:53 – How were disagreements settled within the working group?Management of Cerebral Edema 27:45 – Cerebral edema and elevated ICP; 29:22 – Refractory cerebral edema management; 31:59 – How long was the initial question list?; 35:03 – Quality of evidence; 37:58 – Patient subgroup with the most evidence; 40:10 – Should we be driving up patients’ sodium levels?; 44:56 – Is there a preferred hyperosmolar agent?; 47:45 – Mannitol in acute ischemic stroke; 49:00 – Osmolar therapy and neurologic outcomes; 51:16 – HTS administration; 54:30 – HTS ADE and monitoring; 57:10 – Mannitol osmolality monitoring; 58:20 – Hyperosmolar therapy ADE prevention; 61:00 – Guideline key take-aways; 62:20 – Common research issuesPharmacyToDose.Com@PharmacyToDose on Twitter/InstagramPharmacyToDose@Gmail.com

71 MINAPR 16
Comments
Cerebral Edema Treatment

COVID-19

COVID-19 Special Guest: Andrew Barnes, PharmDDr. Andrew Barnes joins the podcast to discuss the effects of COVID-19. We talk about what Seattle and the University of Washington are doing to help treat this national pandemic. Plus there are plenty of tips throughout the episode for ways you can adapt to COVID-19 in your hospital or health system.PharmacyToDose.Com@PharmacyToDose on Twitter/InstagramPharmacyToDose@Gmail.com

55 MINMAR 26
Comments
COVID-19
success toast
Welcome to Himalaya LearningDozens of podcourses featuring over 100 experts are waiting for you.